



Vyvgart in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

NEUROLOGY · GENERALISED MYASTHENIA GRAVIS

The clinical situation

Vyvgart (efgartigimod alfa-fcab) is an FDA-approved neonatal Fc receptor (FcRn) antagonist for generalised myasthenia gravis (gMG) in adults who are AChR-antibody positive, manufactured by argenx. The IV formulation is a one-hour infusion of 10 mg/kg once weekly for four weeks; additional cycles are scheduled based on clinical response. A subcutaneous formulation (Vyvgart Hytrulo) is also available with shorter administration time. Eligibility requires confirmed AChR-antibody seropositivity, MGFA clinical classification, and pre-treatment screening (vaccinations, infection screen). The IV route requires a licensed infusion centre.

The pathway, 6 steps

- 1 Consultation with neurology.** AChR-antibody confirmation, gMG diagnosis, MGFA classification, and pre-treatment screening documented.
- 2 Formulation selection.** IV (Vyvgart) versus subcutaneous (Vyvgart Hytrulo) — a clinical decision.
- 3 MoHAP named-patient application.** Physician files clinical letter, patient identifier, infusion-facility plan (if IV), and product details (DoH/DHA as applicable).
- 4 US-side sourcing.** Reserve Meds coordinates through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Cold-chain shipment.** Vyvgart ships at 2–8°C with continuous temperature monitoring.
- 6 Arrival & cycle administration.** The licensed facility administers the four-weekly cycle; further cycles per clinical response.

Indicative economics

Reference US cash-pay range: USD 400,000–600,000 annualised depending on cycle frequency (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first cycle, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP (or DoH/DHA) review, keyed to the AChR-positive gMG rationale. **Logistics.** 2–8°C cold-chain coordination to the licensed administration facility. **Concierge case lead.** Named point of contact across cycles. **We are a**

coordinator — not the prescriber, not the dispensing pharmacy, not the infusion centre. All clinical decisions remain with your treating neurologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Vyvgart × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/vyvgart-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team